Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 4/20 | 0.37 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687958 | 1.00 | ALDH1A1 (0.41) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL15726987 | 1.00 | ALDH1A1 (0.41) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL25206318 | 0.91 | JAK3 (0.38) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13498450 | 0.89 | ALDH1A1 (0.54) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1687921 | 0.89 | ALDH1A1 (0.54) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3487800 | 0.89 | ALDH1A1 (0.54) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL463245 | 0.88 | ALDH1A1 (0.48) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL19240724 | 0.87 | ALDH1A1 (0.49) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL19240725 | 0.87 | ALDH1A1 (0.49) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL19240726 | 0.87 | ALDH1A1 (0.49) | ALDH1A1NPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20220008424-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2022-01-13 | — | — | US | disclosed |
| US-20190276446-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2019-09-12 | — | — | US | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-9951056-B2 | Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| EP-2529622-B1 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017156495-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20140135347-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140128414-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8663961-B2 | — | — | 2014-03-04 | — | — | US | disclosed |
| US-8658653-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20140039186-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8563563-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8552010-B2 | Inhibitors of Bruton'S tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8497277-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476284-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008424-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885HPGD 2986/4885 |
| US-20190276446-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | ALDH1A1 3484/4885NPC1 4189/4885HPGD 1097/4885 |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | ALDH1A1 3484/4885NPC1 4189/4885HPGD 1097/4885 |
| US-20140128413-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885HPGD 2986/4885 |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | ALDH1A1 3484/4885NPC1 4189/4885HPGD 1097/4885 |
| US-20140039186-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885HPGD 2986/4885 |
| US-20140128414-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885HPGD 2986/4885 |
| US-20140135347-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885HPGD 2986/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | ALDH1A1 3523/4885NPC1 3716/4885HPGD 1147/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | ALDH1A1 3332/4885NPC1 4775/4885HPGD 2507/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | ALDH1A1 3301/4885NPC1 3638/4885HPGD 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.